SeaStar Medical Reports Strong Q1 2025 Growth

Seastar Medical Holding Corporation ( (ICU) ) has released its Q1 earnings. Here is a breakdown of the information Seastar Medical Holding Corporation presented to its investors.

SeaStar Medical Holding Corporation is a commercial-stage healthcare company specializing in innovative treatments for critically ill patients, particularly those with acute kidney injury (AKI). The company recently reported its financial results for the first quarter of 2025, highlighting significant growth and strategic advancements. SeaStar Medical’s net revenue saw a four-fold increase, driven by the adoption of its QUELIMMUNE therapy, which is designed to improve outcomes for pediatric patients with AKI. Additionally, the company achieved 50% enrollment in its NEUTRALIZE-AKI trial for adult patients, marking a key milestone in its expansion efforts.

The first quarter of 2025 was notable for SeaStar Medical as it reported approximately $293,000 in net revenue, a substantial increase from the previous quarter. This growth was fueled by the successful launch and adoption of the QUELIMMUNE therapy, which has broadened its customer base, including securing a nationally recognized children’s medical center. The company also received two new Breakthrough Device Designations, enhancing its potential for faster regulatory approval and favorable reimbursement dynamics.

Financially, SeaStar Medical reported a net loss of approximately $3.8 million for the quarter, a significant improvement compared to the $12.7 million loss in the same period last year. The reduction in net loss was largely due to the elimination of outstanding debt obligations and convertible notes. The company also reported an increase in cash and long-term investments, totaling $5.3 million as of March 31, 2025, following a successful $6.0 million direct offering.

Looking ahead, SeaStar Medical remains focused on expanding its market presence and advancing its clinical trials. The company is optimistic about the potential for its Selective Cytopheretic Device (SCD) therapy to address unmet needs in the adult AKI market. With ongoing efforts to engage healthcare providers and the anticipated results from the NEUTRALIZE-AKI trial, SeaStar Medical is poised for continued growth and innovation in the healthcare sector.